Pimozide treatment of Sydenham's chorea
K. Shannon,G. Fenichel
DOI: https://doi.org/10.1212/WNL.40.1.186
IF: 9.9
1990-01-01
Neurology
Abstract:Pimozide, a diphenylbutylpiperidine, is similar to haloperidol, has a strong blocking effect on the postsynaptic dopamine receptor, and is approved for use in the United States for the management of Gilles de la Tourette’s syndrome. The usual effective dose in the treatment of Tourette’s syndrome is 3 to 8 mg/d. Transitory sedation is the only common adverse reaction and it usually occurs when therapy is initiated with large doses. Less common dose-related adverse reactions are parkinsonism, weight gain, restless legs, and depression.’ Sydenham’s chorea, an acute encephalopathy of childhood, is a cardinal manifestation of rheumatic fever. Its major features are chorea and emotional lability. The chorea is often severe and exhausting. Sedatives such as diazepam, haloperidol, and phenobarbital are often administered to reduce the movements and the emotional changes. Symptomatic treatment with such drugs usually requires considerable sedation. Pimozide was reported to provide complete relief of symptoms in 1 child with refractory Sydenham’s chorea.2 We have had a similar experience in 2 further cases. Patient 1. A 16-year-old girl developed left hemichorea, mood swings, and recent memory disturbances in October 1988. She was seen by us 2 weeks later and at that time her tonsils were inflamed, the chorea was generalized, and her mood was labile. Group A streptococcus was cultured from her throat, her antistreptolysin 0 titer was 960 Todd Units, and the following test results were normal: antinuclear antibody, Monospot, thyroid function, and ECG. Her infection was treated with penicillin and her movements were treated with diazepam, but she became progressively disabled and bed-confined. In December 1988, she was started on pimozide 1 mg bid with immediate improvement. Within 1 week she was able to walk without falling. After 2 weeks the dose was increased to 2 mg bid, and she became asymptomatic. The pimozide dose was reduced to 1 mg bid in March 1989 and was discontinued in May 1989. She returned to school in March, and was asymptomatic when last seen in June 1989. Patient 2. This 12-year-old girl developed severe generalized chorea and mood change in January 1989. Her antistreptolysis 0 titer was 960 Todd Units. The following test results were normal: thyroid function, antinuclear antibody, and MRI of the brain. She was 1st treated with valproic acid, and then successively with haloperidol, diphenhydramine, and clonazepam. Only transitory relief of symptoms was reported with each drug change. We 1st saw her in June 1989. At that time she had severe generalized chorea and was unable to walk. Pimozide 1 mg bid provided immediate reduction of symptoms, and the dose was increased to 2 mg bid. One week after the dose was increased, she was able to feed herself and walk unassisted. Discussion. The pharmacologic basis of Sydenham’s chorea is believed to be excessive dopamine activity in the basal ganglia.3 Haloperidol reduces the involuntary movements but causes considerable sedation as well. Like haloperidol, pimozide selectively blocks central dopamine receptors. However, unlike haloperidol, it has virtually no effect on norepinephrine receptors.4 This more selective action of pimozide may be responsible for its reduced incidence of adverse side effects. As with any neuroleptic, chronic use of pimozide may be associated with tardive dyskinesia, but the risk is low for short-term, low-dose therapy, and it is outweighed by the benefits to patients who are severely disabled by dyskinetic movements. Pimozide appears to be an effective and well-tolerated treatment for severe Sydenham’s chorea.